QbD Implementation in Biotechnological Product Development Studies

Biotechnological drug development is an extensive area still growing and coming into prominence day by day. Since biotechnological product manufacturing is irreversible, highly expensive, and contains so many critical parameters throughout the process, quality control tests applied to the finished product become inefficacious; therefore, maintaining predefined quality is crucial. Quality by Design (QbD), a systematic approach, is designing and optimizing of formulation and production processes in order to provide a predefined product quality by following a risk and scientific‐based path. Determining the critical variables for biotechnological products and their manufactur‐ ing via risk assessment is the first and most vital stage of QbD approach, before exploring the multivariate relations among the independent and dependent critical variables by mathematical modeling with the assistive technologies. Response Surface Method (RSM), Artificial Neural Network (ANN), and Genetic Algorithm (GA) are some of the assistive technologies used to perform mathematical modeling. After modeling, additional knowledge is vested and this provides the chance to find a range in which the product quality is always ensured, called as “Design space”. So, product quality is procured all along the process by keeping the critical variables under control with less effort, money, and mistakes.

[1]  G. Walsh Pharmaceutical Biotechnology: Concepts and Applications , 2007 .

[3]  P. York,et al.  Quality by Design Approach: Application of Artificial Intelligence Techniques of Tablets Manufactured by Direct Compression , 2012, AAPS PharmSciTech.

[4]  Tom Fletcher,et al.  Designing Culture Media for Recombinant Protein Production A Rational Approach , 2005 .

[5]  Feng Li,et al.  Cell culture processes for monoclonal antibody production , 2010, mAbs.

[6]  Jochen Strube,et al.  Challenges in biotechnology production—generic processes and process optimization for monoclonal antibodies , 2005 .

[7]  I. Arora Chromatographic Methods for the Purification of Monoclonal Antibodies and their Alternatives:A Review , 2013 .

[8]  M. Khan,et al.  Quality by Design for Biopharmaceutical Drug Product Development , 2015, AAPS Advances in the Pharmaceutical Sciences Series.

[9]  Buket Aksu,et al.  A quality by design approach using artificial intelligence techniques to control the critical quality attributes of ramipril tablets manufactured by wet granulation , 2013, Pharmaceutical development and technology.

[10]  Shruti Chopra,et al.  QUALITY BY DESIGN (QBD) IN PHARMACEUTICAL INDUSTRY , 2015 .

[11]  Nayana V. Pimpodkar,et al.  Quality by Design , 2016 .

[12]  Christoph Herwig,et al.  An Integrated Downstream Process Development Strategy along QbD Principles. , 2014, Bioengineering.

[13]  R. Bayer,et al.  Recovery and purification process development for monoclonal antibody production , 2010, mAbs.

[14]  Buket Aksu,et al.  A Flexible Regulatory Approach for Different Raw Materials Suppliers Using QbD Principles , 2013 .

[15]  Anurag S Rathore,et al.  Roadmap for implementation of quality by design (QbD) for biotechnology products. , 2009, Trends in biotechnology.

[16]  Ramaji K. Varu,et al.  Opportunities and Challenges to Implementing Quality by Design Approach in Generic Drug Development , 2010 .

[17]  Sandipan Roy,et al.  Quality by design : A holistic concept of building quality in pharmaceuticals , 2012 .

[18]  Salim Charaniya,et al.  Bioprocess and Fermentation Monitoring , 2013 .

[19]  G. Weiner Building better monoclonal antibody-based therapeutics , 2015, Nature Reviews Cancer.

[20]  A. Rathore,et al.  Quality by Design for Biotechnology Products , 2009 .

[21]  Jochen Strube,et al.  Trends in Upstream and Downstream Process Development for Antibody Manufacturing. , 2014, Bioengineering.